Khan, Parvez
Siddiqui, Jawed Akhtar
Kshirsagar, Prakash G.
Venkata, Ramakanth Chirravuri
Maurya, Shailendra Kumar
Mirzapoiazova, Tamara
Perumal, Naveenkumar
Chaudhary, Sanjib
Kanchan, Ranjana Kumari
Fatima, Mahek
Khan, Md Arafat
Rehman, Asad Ur
Lakshmanan, Imayavaramban
Mahapatra, Sidharth
Talmon, Geoffrey A.
Kulkarni, Prakash
Ganti, Apar K.
Jain, Maneesh
Salgia, Ravi
Batra, Surinder Kumar
Nasser, Mohd Wasim
Funding for this research was provided by:
National Institutes of Health (R01CA247471, R01CA247471, R01CA247471, R01CA218545)
Article History
Received: 8 April 2022
Accepted: 6 December 2022
First Online: 4 January 2023
Declarations
:
: All mouse experiments/procedures were duly approved and performed as per Institutional animal care and use committee (IACUC) guidelines in accordance with the National Institute of Health (NIH). The animals were maintained as per IACUC guidelines in the University of Nebraska medical center (UNMC) animal house facility (IACUC # 17–045-06-FC).
: All authors agree with the content of the manuscript and consent to publication.
: SKB is co-founder of Sanguine Diagnostics and Therapeutics, Inc. AKG has served on Advisory Boards for AstraZeneca, Jazz pharmaceuticals, Sanofi–Genzyme, Beigene; received research support from Takeda Pharmaceuticals, Merck, TAB Biosciences, IOVANCE, and Mirati Therapeutics; is a consultant for Flagship Biosciences and serves on the DSMC for Y-mAbs Therapeutics. Other authors declare no competing interests.